Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Side-effect expectations from COVID-19 vaccination: Findings from a nationally representative cross-sectional survey (CoVAccS – wave 2)

Louise E. Smith a,b,*, Julius Sim c, Richard Amlot b,d, Megan Cutts e, Hannah Dasch a,f, Nick Sevdalis b,f, G. James Rubin a,b, Susan M. Sherman e

a King’s College London, Institute of Psychiatry, Psychology and Neuroscience, UK
b NIHR Health Protection Research Unit in Emergency Preparedness and Response, UK
c Keele University, School of Medicine, UK
d UK Health Security Agency, Behavioural Science and Insights Unit, UK
e Keele University, School of Psychology, UK
f King’s College London, Centre for Implementation Science, UK

ARTICLE INFO

Keywords:
Adverse effects
COVID-19
Expectation
Nocebo effect
Vaccination

ABSTRACT

Objectives: Concern about side effects is one of the most common reasons for refusing vaccination. Side-effect expectations are known to predict perception of side effects. We aimed to investigate the percentage of people who thought side effects from COVID-19 vaccination were likely and investigate factors associated with side-effect expectation.

Methods: Online cross-sectional survey of 1470 UK adults who had not been vaccinated for COVID-19 (conducted 13 to 15 January 2021). We asked participants how likely they thought side effects from COVID-19 vaccination were. Linear regression analyses were used to investigate associations with side-effect expectations.

Results: Most participants were uncertain whether they would experience side effects from a COVID-19 vaccine; only a minority reported that side effects were very likely (9.4%, 95% CI 7.9% to 10.9%, n = 138/1470). Personal and clinical characteristics, general, and COVID-19 vaccination beliefs and attitudes explained 29.7% of the variance in side-effect expectation, with COVID-19 vaccination beliefs alone accounting for 17.2%. Side-effect expectations were associated with: older age, being clinically extremely vulnerable to COVID-19, being afraid of needles, lower perceived social norms for COVID-19 vaccination, lower perceived necessity and safety of COVID-19 vaccination, and perceived lack of information about COVID-19 and vaccination.

Conclusions: Side-effect expectation was associated with believing that COVID-19 vaccination was unsafe, ineffective and that others would be less likely to approve of you having a COVID-19 vaccination. Communications should emphasise the safety, effectiveness, and widespread uptake of vaccination, while promoting accurate perceptions of the incidence of vaccination side effects.

1. Introduction

Fears about vaccine side effects are among the most common reasons for refusal of vaccinations, including during the H1N1 influenza pandemic. [1–3] At the time of writing, three COVID-19 vaccines had been approved for use in the UK: the Pfizer/BioNTech (approved 2 December 2020), AstraZeneca (30 December 2020), and Moderna (8 January 2021) vaccines. [4–6] Clinical trial data indicate that injection site adverse events are very common (up to 83% Pfizer/BioNTech, 67% AstraZeneca, 89% Moderna). [7–9] Common systemic adverse effects include fatigue (Pfizer/BioNTech up to 59%, AstraZeneca 70%), headache (Pfizer/BioNTech up to 52%, AstraZeneca 68%), and fever (Pfizer/BioNTech up to 16%, AstraZeneca 18%). [7,8,10] Older people experience fewer adverse effects. [8,9] There is some evidence that side effects may be more common (Pfizer/BioNTech) and severe (Moderna) following the second dose of the vaccine. [8–10]

The cause of adverse effects from vaccination is not always clear. While some may be caused by biological mechanisms of the vaccine, psychological factors also play a part. Side-effect expectations are important, fuelling the ‘nocebo effect’, a phenomenon whereby the expectation of symptoms is self-fulfilling. The association between side-effect expectations and subsequent reporting of side effects has been
found for a range of medications, including cancer treatments, rheumatoid arthritis medication, and child vaccination. [11–13] A systematic review of factors associated with expectations of side effects from medical interventions found some evidence that negative beliefs about medications was associated with greater side-effect expectations. [14]

The aim of this study was to estimate the percentage of the UK population who expected side effects from the COVID-19 vaccine, and to investigate associations between side-effect expectations and personal and clinical characteristics, general vaccine beliefs and attitudes, and COVID-19 vaccination beliefs and attitudes.

2. Methods

This study reports data from the second wave of the COVID-19 vaccination acceptability study (CoVAccS). Full methods of the study have been reported elsewhere. [15]

2.1. Design

Cross-sectional online survey hosted on Qualtrics. Data were collected from 13 to 15 January 2021.

2.2. Participants

1500 participants were recruited through Prolific’s UK online research panel. Participants were eligible for the study if they were aged eighteen years or over, lived in the UK, and had not completed our previous survey (n > 31,000 eligible participants). [16] We used quota sampling based on age, sex, and ethnicity so that participant characteristics were broadly reflective of those in the UK population. Participants provided informed consent to take part in the study before being able to commence the survey. Upon completion of the survey, participants were paid £2.

For this study, we included participants if they indicated that they had not yet received a COVID-19 vaccine (n = 1470).

2.2.1. Measures

Full survey materials are available online. [17]

Side-effect expectation was measured by a single item asking participants how likely they thought it was that they “would get side effects from a coronavirus vaccine” on an 11-point scale, from “extremely unlikely” (0) to “extremely likely” (10).

To measure general vaccination beliefs and attitudes, we asked participants to what extent they agreed that vaccination is a good thing in general and that they were afraid of needles, on an 11-point scale from “strongly disagree” (0) to “strongly agree” (10).

We measured COVID-19 vaccination beliefs and attitudes using 21 statements investigating: perceived effectiveness and safety of COVID-19 vaccination; barriers and facilitators to vaccination; perceived information sufficiency about COVID-19 and the vaccine; social norms about vaccination; beliefs about profiteering; and beliefs concerning the impact of vaccination on restrictions. Participants were asked to what extent they agreed with the statements from “strongly disagree” (0) to “strongly agree” (10). Sixteen of these items were included in a principal components analysis, which identified five components accounting for 68% of the variance in the original items: social norms regarding vaccination, necessity of vaccination, safety of the vaccine, adequacy of information about the vaccine, and freedom from restrictions through the vaccine. [15]

We asked participants for their age, sex, ethnicity, religion, highest level of qualification, and employment status. Participants were asked whether they, or someone they lived with, had a medical condition that made them extremely clinically vulnerable to COVID-19. [18] We also asked participants if they worked or volunteered in roles critical to COVID-19 (“key worker”). [19]

2.2.2. Ethics

We obtained ethical approval for this study from Keele University’s Research Ethics Committee (reference: PS-200129).

2.2.3. Power

A sample size of 1500 was chosen to allow a sufficiently high ratio of cases to estimated parameters, avoiding overfitting and loss of generalizability in the regression model. [21]

2.2.4. Analysis

We categorised respondents as expecting side effects from COVID-19 vaccination using an a priori cut-offs on the likelihood scale (zero to two = very unlikely, three to seven = uncertain, eight to ten = very likely). [15,16]

To investigate factors associated with side-effect expectations we used a linear regression model, using the original 0 to 10 scale as the outcome measure. Variables were entered into the model in blocks: personal and clinical characteristics (block 1); general beliefs and attitudes relating to vaccination (block 2); and beliefs and attitudes relating to COVID-19 vaccination (block 3).

To control the rate of Type 1 errors, we set statistical significance at p ≤ .01 and therefore calculated 99% confidence intervals (CIs) for regression coefficients.

3. Results

The 1470 participants included in analyses were broadly representative of the UK population (50.8%, n = 746 female; 85.2%, n = 1246 white ethnicity; mean age 45.5 years, SD = 15.5, range 18 to 80 years).

Most participants were uncertain about the likelihood of side effects from COVID-19 vaccination, with the midpoint of the scale being the most selected (modal) response. When using our a priori cut-offs, a minority of participants reported that side effects from a COVID-19 vaccine were very likely (9.4%, 95% CI 7.9% to 10.9%, n = 138/1470; Fig. 1). One-third of participants thought that side effects were very unlikely (33.1%, 95% CI 30.7% to 35.5%, n = 486/1470), while 57.6% (95% CI 55.0% to 60.1%, n = 846/1470) were uncertain.

1427 participants had complete data and were included in regression analyses. The overall regression model explained 29.7% of the variance, with COVID-19 vaccination beliefs and attitudes alone explaining 17.2% of the variance. Side-effect expectation was associated with: older age; being clinically extremely vulnerable to COVID-19 oneself; being afraid of needles; lower perceived social norms regarding COVID-19 vaccination; perceiving COVID-19 vaccination to be less necessary; poorer perceived safety of COVID-19 vaccination; and perceived inadequacy of information about vaccination (Table 1).

4. Discussion

Despite clinical trial data indicating that most people will go on to develop local or systemic adverse effects of COVID-19 vaccination, [7–9] participants were uncertain about the likelihood of side effects from COVID-19 vaccination and only a minority thought side effects were very likely. Under-estimation of the likelihood of side effects is unusual for medications. [20] In this instance, low levels of expectation may increase uptake of the first dose of the vaccine. [1–5] How the unexpected occurrence of side effects might affect uptake of the second dose is less clear. Since data collection, evidence indicating that the AstraZeneca vaccine may be linked to unusual blood clots with low blood platelets (published 7 April 2021) has been the focus of much media attention. [21] Research has shown that coverage of medication side effects in the news media increases symptom reporting. [22] Preliminary evidence suggests that coverage of a possible link between the AstraZeneca vaccine and blood clots may have affected side-effect expectations. [23] However, these data remain important by virtue of quantifying the prevalence of side-effect expectations and associated...
Fig. 1. Frequency distribution of side-effect expectations (0 = “extremely unlikely” to 10 = “extremely likely”).

Table 1
Results of the full linear regression model analysing associations with side-effect expectation (adjusted $R^2 = 0.297$). Parameter estimates relate to the full model containing all predictors. The unstandardized regression coefficients represent the change in likelihood of side effects for a one-unit increase in the predictor variable (or, for dummy variables, a shift from the reference category to the category concerned). The model was based on 1427 participants with complete data.

| Predictor variable                                      | Level                      | Standardized coefficient | Unstandardized coefficient | 99% confidence interval | $p$ value |
|---------------------------------------------------------|----------------------------|--------------------------|---------------------------|-------------------------|-----------|
| Block 1 – personal and clinical characteristics $^a$    |                            |                          |                           |                         |           |
| Age (years)                                             | 0.107                      | 0.017                    | 0.006 to 0.028            | $< 0.001^*$             |           |
| Sex (reference: female)                                 |                            |                          |                           |                         |           |
| Male                                                    | $-0.029$                   | $-0.185$                 | $-0.471$ to $0.102$       | 0.096                   |           |
| Ethnicity (reference: black and minority ethnic)        |                            |                          |                           |                         |           |
| White                                                   | $-0.029$                   | $-0.198$                 | $-0.653$ to $0.257$       | 0.262                   |           |
| Religion (reference: none)                              |                            |                          |                           |                         |           |
| Christian                                               | $-0.026$                   | $-0.128$                 | $-0.440$ to $0.184$       | 0.307                   |           |
| Other                                                   | $0.021$                    | 0.193                    | $-0.499$ to $0.796$       | 0.262                   |           |
| Qualifications (reference: other)                       |                            |                          |                           |                         |           |
| Degree equivalent or higher                             | $-0.008$                   | $0.038$                  | $-0.332$ to $0.255$       | 0.736                   |           |
| Employment status (reference: not working/other)        |                            |                          |                           |                         |           |
| Part-time                                               | $0.053$                    | 0.341                    | $-0.091$ to $0.773$       | 0.042                   |           |
| Full-time                                               | $0.028$                    | 0.136                    | $-0.214$ to $0.486$       | 0.317                   |           |
| Key worker (reference: not key worker)                  |                            |                          |                           |                         |           |
| Key worker                                              | $0.005$                    | 0.025                    | $-0.307$ to $0.357$       | 0.845                   |           |
| Extremely clinically vulnerable – self (reference: no)  | $0.061$                    | 0.354                    | $0.097$ to $0.702$        | 0.099$                  |           |
| Extremely clinically vulnerable – household member       | $0.004$                    | 0.025                    | $-0.356$ to $0.405$       | 0.868                   |           |
| Block 2 – general vaccination beliefs and attitudes $^b$|                            |                          |                           |                         |           |
| Vaccination is generally good (0 – 10) $^d$             | $0.018$                    | 0.026                    | $-0.096$ to $0.148$       | 0.577                   |           |
| I am afraid of needles (0 – 10) $^d$                    | $0.068$                    | 0.050                    | $0.006$ to $0.094$        | 0.003$                  |           |
| Block 3 – beliefs and attitudes about COVID-19 vaccination $^c$ |                      |                          |                           |                         |           |
| Component: social norms regarding COVID-19 vaccination  | $-0.209$                   | $-0.517$                 | $-0.703$ to $-0.330$      | $< 0.001^*$             |           |
| Component: the necessity of vaccination (−3.90 to 3.67) | $-0.144$                   | $-0.349$                 | $-0.527$ to $-0.171$      | $< 0.001^*$             |           |
| Component: safety of the vaccine (−3.91 to 2.56)        | $-0.454$                   | $-1.104$                 | $-1.285$ to $-0.923$      | $< 0.001^*$             |           |
| Component: adequacy of information about vaccination (−3.77 to 3.41) | $-0.076$                   | $-0.187$                 | $-0.338$ to $-0.035$      | 0.002$                  |           |
| Component: freedom from restrictions through the vaccine (−2.41 to 3.26) | $-0.017$                   | $-0.041$                 | $-0.188$ to $0.107$       | 0.478                   |           |
| The way the coronavirus vaccines are being given against the manufacturers’ recommendations (0 – 10) $^d$ | $0.014$                    | 0.011                    | $-0.037$ to $0.060$       | 0.550                   |           |
| Only people who are at risk of serious illness from coronavirus need to be vaccinated (0 – 10) $^d$ | $0.005$                    | 0.004                    | $-0.052$ to $0.061$       | 0.841                   |           |
| Widespread coronavirus vaccination is just a way to make money for vaccine manufacturers (0 – 10) $^d$ | $0.026$                    | 0.024                    | $-0.051$ to $0.100$       | 0.409                   |           |

$^a$ variables in this block explained 1.3% of the variance.

$^b$ variables in this block explained 0.3% of the variance.

$^c$ variables in this block explained 17.2% of the variance.

$^d$ 0 = strongly disagree, 10 = strongly agree.
factors in the absence of much information at the start of the vaccine rollout in the UK.

Unsurprisingly, poorer perceived safety of COVID-19 vaccination was associated with greater side-effect expectations. [11] In line with research finding that negative beliefs about vaccinations were associated with increased side-effect expectations, [20] we also found that lower perceived necessity of COVID-19 vaccination was associated with greater side-effect expectations. Lower perceived social norms for COVID-19 vaccination (i.e. being less likely to think that others would approve of you having a COVID-19 vaccine) were also associated with greater side-effect expectations. This may be an example of the ‘horn effect’ (opposite of the ‘halo effect’), whereby a negative impression of something negatively influences perceptions in a related area.

Perceived lack of information about COVID-19 and COVID-19 vaccination was associated with greater side-effect expectations. As side-effect expectations are lower than suggested by clinical trial data, communications should aim to promote an accurate perception of the incidence of side effects, and the mild and temporary nature of side effects likely to be experienced by most recipients of a COVID-19 vaccine.

Although adverse effects are more likely in younger people, [8-10] we found that older people had greater side-effect expectations. This may be reflective of the stage in the vaccination rollout in the UK at the time of this study (January 2021), with older people being offered the vaccine first. As the rollout progresses, and people learn about others developing side effects following vaccinations, [24,25] side-effect expectations in younger age groups may increase. Being clinically extremely vulnerable to COVID-19 was also associated with greater side-effect expectations. There is evidence that side-effect expectations are associated with currently experiencing symptoms. [14] As people who were clinically extremely vulnerable to COVID-19 reported having an underlying medical condition, they may have been more likely to be experiencing symptoms at the time of data collection.

It is important that people are informed transparently and accurately about the likelihood and severity of side effects from vaccination. While educational interventions may be an attractive option, there is mixed evidence for their effect on vaccine uptake. [26,27] Using simple infographics (e.g. pictographs) and improving the clarity and readability of information increase the accuracy of side-effect expectations. [28,29]

Our results indicate that side-effect expectations at the start of the COVID-19 vaccine rollout in the UK were low compared to rates described by clinical trial data. Therefore, bringing people’s expectations in line with these data may increase the incidence of nocebo-related symptoms. However, side-effect expectations have increased since the MHRA’s announcement that the AstraZeneca vaccine may be linked to unusual blood clots related to low blood platelets (published 7 April 2021). [23] Providing reassurance about the typically transitory and non-harmful nature of side-effects may be a useful strategy in increasing initial vaccine uptake and reducing long-term attrition among those offered booster jabs (offered in the UK since October 2021).

As this study is cross-sectional, we cannot infer direction of causality between attitudes and beliefs and side-effect expectations. Further, the survey methodology used cannot rule out self-selection bias affecting the study results. To the best of our knowledge, there is no validated measure of side-effect expectation. We used a single item to measure side-effect expectation, with regard to the established psychometric properties of a 0 to 10 numerical rating scale format. [30] This item was based on previous research conducted by our group. [11] Not all potential variables that could have been associated with side-effect expectations were investigated due to space limitations in the survey.

5. Conclusion

At the start of the COVID-19 vaccine rollout in the UK, most people were unsure whether side effects from vaccination were likely. Media coverage of side effects and seeing people experience side effects as the vaccine rollout continues may heighten side-effect expectations. COVID-19 vaccination beliefs and attitudes were associated with side-effect expectations. In particular, side-effect expectations were associated with poorer perceived safety and effectiveness of the vaccine, thinking that others were less likely to approve if you were to have the vaccine, and a perceived lack of information about COVID-19 and vaccination. Public health communications should emphasise the safety, effectiveness, and widespread uptake of COVID-19 vaccination, while also promoting accurate perceptions of the incidence and nature of side effects from vaccination.

Sources of funding

Data collection was funded by a Keele University Faculty of Natural Sciences Research Development award to SS, JS and NS, and a King’s COVID Appeal Fund award granted jointly to LS, GJR, RA, NS, SS and JS. NS’ research is supported by the National Institute for Health Research (NIHR) Applied Research Collaboration (ARC) South London at King’s College Hospital NHS Foundation Trust. NS is a member of King’s Improvement Science, which offers co-funding to the NIHR ARC South London and is funded by Kings Health Partners (Guys and St Thomas NHS Foundation Trust, King’s College Hospital NHS Foundation Trust, Kings College London and South London and Maudsley NHS Foundation Trust), and the Guy’s and St Thomas’ Foundation. The views expressed are those of the authors and not necessarily those of the NIHR, the charities, UK Health Security Agency or the Department of Health and Social Care.

Declaration of Competing Interest

All authors have completed the Unified Competing Interest form at http://www.icmje.org/coi_disclosure.pdf and declare that data collection was funded by a Keele University Faculty of Natural Sciences Research Development award to SS, JS and NS, and a King’s COVID Appeal Fund award granted jointly to LS, GJR, RA, NS, SS and JS. NS is the director of the London Safety and Training Solutions Ltd., which offers training in patient safety, implementation solutions and human factors to healthcare organisations and the pharmaceutical industry; RA is employed by the UK Health Security Agency. The other authors have no conflicts of interest to declare.

References

[1] A. Bish, L. Yardley, A. Nicoll, S. Michie, Factors associated with uptake of vaccination against pandemic influenza: a systematic review, Vaccine. 29 (2011) 6472-6484.
[2] L.E. Smith, R. Amlot, J. Weinman, J. Yiend, G.J. Rubin, A systematic review of factors affecting vaccine uptake in young children, Vaccine. 35 (2017) 6059-6069.
[3] M.P. Yeung, F.L. Lam, R. Coker, Factors associated with the uptake of seasonal influenza vaccination in adults: a systematic review, J Public Health (Oxf). 38 (2016) 746–753.
[4] Medicines and Healthcare products Regulatory Agency: Regulatory approval of Pfizer/BioNTech vaccine for COVID-19, Available from, https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19.
[5] Medicines and Healthcare products Regulatory Agency: Regulatory approval of COVID-19 Vaccine AstraZeneca, Available from, https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca.
[6] Medicines and Healthcare products Regulatory Agency: Regulatory approval of COVID-19 Vaccine Moderna, Available from, https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-moderna.
[7] P.M. Folegatti, K.J. Ewer, P.K. Aley, et al., Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial, Lancet. 396 (2020) 467–478.
[8] F.P. Polack, S.J. Thomas, N. Kitchin, et al., Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine, N. Engl. J. Med. 383 (2020) 2603–2615.
[9] L.R. Baden, H.M. El Sahly, B. Essink, et al., Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine, N. Engl. J. Med. 384 (2021) 403–416.
[10] C. Menni, K. Klæser, A. May, et al., Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVId symptom study app in the UK: a prospective observational study, Lancet Infect. Dis. 21 (2021) 939–949.
[11] L.E. Smith, J. Weinman, R. Amlot, J. Yiend, G.J. Rubin, Parental expectation of side effects following vaccination is self-fulfilling: a prospective cohort study, Ann. Behav. Med. 53 (2018) 267–282.
[12] Y. Nestoriuc, E.J. Orav, M.H. Liang, R. Horne, A.J. Barsky, Prediction of nonspecific side effects in rheumatoid arthritis patients by beliefs about medicines, Arthritis Care Res. 62 (2010) 791–799.

[13] C. Fletcher, C. Wilson, A.D. Hutchinson, A.A. Grunfeld, The relationship between anticipated response and subsequent experience of cancer treatment-related side effects: a meta-analysis comparing effects before and after treatment exposure, Cancer Treat. Rev. 68 (2018) 86–93.

[14] L.E. Smith, R.K. Webster, G.J. Rubin, A systematic review of factors associated with side-effect expectations from medical interventions, Health Expect. 23 (2020) 731–758.

[15] S.M. Sherman, J. Sim, M. Cutts, et al., COVID-19 vaccination acceptability in the UK at the start of the vaccination programme: a nationally representative cross-sectional survey (CoVAccS – wave 2), Public Health (2021), https://doi.org/10.1016/j.puhe.2021.10.005. In press.

[16] S.M. Sherman, L.E. Smith, J. Sim, et al., COVID-19 vaccination intention in the UK: results from the COVID-19 vaccination acceptability study (CoVAccS), a nationally representative cross-sectional survey, Hum Vaccin Immunother. 17 (2021) 1612–1621.

[17] COVID-19 vaccination acceptability in the UK January 2021 (CoVAccS - Wave 2), Available from: https://osf.io/ewch3/?view_only=8d25c3247e240e28e61c9885804801.

[18] NHS: Who is at higher risk of coronavirus (clinically extremely vulnerable), Available from: https://www.nhs.uk/conditions/coronavirus-covid-19/people-at-higher-risk/whos-at-higher-risk-from-coronavirus/.

[19] Cabinet Office, Department for Education: Children of critical workers and vulnerable children who can access schools or educational settings. Available from: https://www.gov.uk/government/publications/coronavirus-covid-19-maintaining-educational-provision/guidance-for-schools-colleges-and-local-authorities-on-maintaining-educational-provision.

[20] R.K. Webster, J. Weinman, G.J. Rubin, How does the side-effect information in patient information leaflets influence peoples’ side-effect expectations? A cross-sectional national survey of 18- to 65-year-olds in England, Health Expect. 20 (2017) 1411–1420.

[21] European Medicines Agency: AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets Share. Available from: https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood.

[22] K. Faasne, G. Gamble, T. Cundy, K.J. Petrie, Impact of television coverage on the number and type of symptoms reported during a health scare: a retrospective post observational study, BMJ Open 2 (2012).

[23] Allington D, Duffy B, Monham-Hall V, McAndrew S, Muskín G. Covid-19 vaccines: confidence, concerns and behaviours. Available from: https://www.kcl.ac.uk/policy-institute/assets/covid-19-vaccines-confidence-concerns-behaviours.pdf.

[24] R.K. Webster, J. Weinman, G.J. Rubin, A systematic review of factors that contribute to nocebo effects, Health Psychol. 35 (2016) 1334–1355.

[25] K. Faasne, A. Grey, R. Jordan, S. Garland, K.J. Petrie, Seeing is believing: impact of social modeling on placebo and nocebo responding, Health Psychol. 34 (2015) 880–885.

[26] J. Kaufman, R. Ryan, L. Walsh, et al., Face-to-face interventions for informing or educating parents about early childhood vaccination, Cochrane Database Syst. Rev. 5 (CD010038) (2018).

[27] European Centre for Disease Prevention and Control, Catalogue of interventions addressing vaccine hesitancy. Stockholm, ECDC, 2017. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Catalogue-interventions-vaccine-hesitancy.pdf.

[28] A.R. Tait, T. Voepel-Lewis, B.J. Zikmund-Fisher, A. Fagerlin, The effect of format on parents’ understanding of the risks and benefits of clinical research: a comparison between text, tables, and graphics, J. Health Commun. 15 (2010) 487–501.

[29] C. Pires, M. Vigario, A. Cavaco, Readability of medicinal package leaflets: a systematic review, Rev. Saude Publica 49 (2015).

[30] S. Safikhani, K.S. Gries, J.J. Trudeau, et al., Response scale selection in adult pain measures: results from a literature review, J Patient Rep Outcomes. 2 (2017) 40.